Displaying items by tag: income

(New York)

Safe 5% yields sound very enticing right now don’t they? Well, they are actually not as hard to find as you think if you take a broader perspective. That perspective is to look at standard municipal bonds and examine their real-world yields, or how they compare to taxable bonds. For instance, for a couple living in California with a $250k per year income, a municipal bond yielding 3.0% is equivalent to a taxable bond yielding a whopping 5.8%. This is because of the new tax system brought in by Republicans. One muni expert comments that “I would argue that munis are more attractive than they’ve ever been because, with the loss of various deductions, including SALT, one’s taxable income is higher than it’s ever been”.

FINSUM: This is a very good insight and one to which HNW individuals and advisors need to pay attention. Once investors really come around to this, it could spark a muni bond run.

(New York)

With clients aging, valuations high, and rates uncertain, many may be looking for some good income stocks. Look now further than utilities, says Barron’s. In particular, the Reaves Utility Income Fund, which conceives utilities more broadly and includes telecom and interstate gas properties. The overall view for utilities is strong as they are relatively stable during periods of changing rates. Right now they average yields in the mid 3% range and they seem to be able to deliver growth of 5-7% per year. Valuations also look reasonable.

FINSUM: Barron’s paints a rosy picture of the utilities sector, but if rates head head north it could be a tough time. That said, we think rates and yields are going to stay reasonably stable, so these might be a good buy.

(New York)

Many investors are currently worried about the bond market. There is a lot of uncertainty over just how much rates and yields will rise and what that might mean for the economy. Well, Bloomberg is taking a strong stand on the issue, arguing that a bond Armageddon is on the way. The paper says that all the focus has been on ten-years, but that 30s might be where the danger is. They are within shouting distance of their 2015-2017 highs, and are very close to the 3.24% level, which would signal the difference between an orderly selloff and a full-on rout.

FINSUM: There may be some short-term volatility, but our overall view is that there won’t be a cataclysm in bonds. Global populations are aging and people need income. We expected yields to stay in check and spreads to narrow even if sovereign yields rise.

(New York)

After years in the doldrums, the country (and world) now seems to be on a definitive path to higher interest rates. This reality has set the markets on fire, with bonds dropping and equities swinging all over the map. Understandably then, investors are looking for safe income even as rates rise, especially those who are headed towards retirement. In response, Barron’s has searched for companies whose free cash flow exceeds their dividend as a way of finding income one can rely on. The names that come up when doing this sort of screen also resonate a sense of stability just by their stature, and include UPS, Cisco, and JP Morgan. Walmart, Pfizer, and 3M are also in the mix, amongst others.

FINSUM: Companies with stable and positive free cash flow margins seem like a good bet for maintaining or raising dividends.

(New York)

A lot of investors are looking for income, and over the last several years it has been hard to come by. While yields are rising, they are still very low by historical standards. With that in mind, Barron’s has run a piece selecting the best income stocks from a sector not considered as much as it should be—biotech. Many biotech companies have strong overseas cash flow, and solid yields. For instance, Pfizer, which rose just over 13% last year, sports a 3.7% yield. Abbvie and Amgen are also good looking stocks, both offering dividends just below 3%. Eli Lilly, Johnson & Johnson, and Bristol-Myers Squibb are also names to look at.

FINSUM: These are definitely some good names to look at, especially as there has not been much focus on biotech for income over the last year.